News >

Ponatinib Maintains Benefit in Chronic-Phase CML at 5 Years

Jason Harris
Published: Thursday, Mar 22, 2018

Jorge Cortes, MD
Jorge Cortes, MD
Ponatinib (Iclusig) maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML), according to 5-year results from the pivotal PACE trial published in the journal Blood.

Overall, the PACE trial included 449 patients who received ponatinib at a starting dose of 45 mg daily. Patients were heavily pretreated, with an estimated 93% and 56% of patients having previously received ≥2 TKIs and ≥3 TKIs, respectively.

At a minimum of 48 months’ follow-up (data cutoff: August 3, 2015), 110 of 270 CP-CML patients continued to receive ponatinib. The median durations of MCyR (range 2.7 to >50 months) and MMR (range 1.7 to >50 months) had not yet been reached.

In the overall 449-patient population, 150 patients had experienced AOEs at 4 years. Some patients had more than 1 type of AOE, with cardiac vascular, peripheral vascular, and cerebrovascular arterial occlusive events occurring in 21%, 12%, and 9% of patients, respectively. Arterial occlusive serious adverse reactions were reported for 22% of patients, including 12% cardiac vascular, 8% peripheral vascular, and 7% cerebrovascular. Venous thromboembolic events were reported in 6% of patients.

Ponatinib initially received an accelerated approval from the FDA in 2012 based on earlier findings from the PACE trial.


  1. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial [published online March 22, 2018]. Blood. doi:
  2. Cortes JE, Pinilla-Ibarz J, Le Coutre PD, et al. 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia. J Clin Oncol 34, 2016 (suppl; abstr 7013)..


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.